News
12-01-2014, 06:04 AM
Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag and Sienna+ magnetic sentinel lymph node biopsy system in the management of breast cancer.
More... (http://www.news-medical.net/news/20141201/Endomagnetics-gets-FDAs-IDE-approval-to-begin-clinical-trial-of-SentiMag-and-Sienna2b-system.aspx)
More... (http://www.news-medical.net/news/20141201/Endomagnetics-gets-FDAs-IDE-approval-to-begin-clinical-trial-of-SentiMag-and-Sienna2b-system.aspx)